Health Care & Life Sciences » Biotechnology | GeneOneLifeScience Inc.

GeneOneLifeScience Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
8,363
6,492
1,414
15,599
23,730
11,898
Depreciation, Depletion & Amortization
1,894
1,636
1,124
1,133
1,104
1,294
Other Funds
-
-
37
-
-
8,339
Funds from Operations
3,168
3,785
2,526
7,647
10,018
2,414
Changes in Working Capital
821
374
1,748
1,000
522
4,855
Net Operating Cash Flow
2,347
4,159
778
6,647
10,540
7,269
Capital Expenditures
225
740
2,124
2,131
413
Purchase/Sale of Investments
10,200
8,953
1,216
-
-
Net Investing Cash Flow
9,922
9,616
898
2,158
389
Issuance/Reduction of Debt, Net
9,408
1,900
295
24,864
25,547
Net Financing Cash Flow
4,670
15,176
2,481
25,191
3,956
Net Change in Cash
2,860
1,405
2,438
16,812
15,244
Free Cash Flow
2,556
4,862
1,261
8,753
10,903
Deferred Taxes & Investment Tax Credit
-
14
1,198
780
385
149
Other Sources
6
104
17
34
24
Change in Capital Stock
4,738
17,075
2,223
327
21,590
Exchange Rate Effect
45
4
76
426
359
Other Uses
59
26
6
62
-

About GeneOneLifeScience

View Profile
Address
Unit 1903, Keungil Tower
Seoul SL 06142
Korea, Republic Of
Employees -
Website http://www.genels.com
Updated 07/08/2019
GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.